A091304
|
Alliance
|
A Phase I /Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma
|
Adult CIRB - Early Phase Emphasis
|
Completed
|
|
A091401
|
Alliance
|
Randomized Phase II Study Of Nivolumab With Or Without Ipilimumab In Patients With Metastatic Or Unresectable Sarcoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A091404
|
Alliance
|
A Phase II Study of Enzalutamide (NSC# 766085) for Patients with Androgen Receptor Positive Salivary Cancers
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A091603
|
Alliance
|
A Randomized Phase II Trial of Adjuvant Nivolumab or Expectant Observation Following Neoadjuvant Ipilimumab Plus Nivolumab and Surgical Resection of High-Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma
|
Adult CIRB - Late Phase Emphasis
|
Completed
|
|
A091605
|
Alliance
|
A Randomized Phase II Study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti- PD1 antibody plus Stereotactic Body Radiation therapy in advanced Merkel Cell Carcinoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A091802
|
Alliance
|
Phase II Randomized Trial of Avelumab Plus Cetuximab versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin (cSCC)
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A091902
|
Alliance
|
A Multicenter Phase II Trial of Paclitaxel with and without Nivolumab in Taxane Naive, and Nivolumab and Cabozantinib in Taxane Pretreated Subjects with Angiosarcoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A091903
|
Alliance
|
A Randomized Phase II Trial of Adjuvant Nivolumab with or Without Cabozantinib in Patients with Resected Mucosal Melanoma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A092001
|
Alliance
|
Phase 2 Randomized Trial of Neoadjuvant or Palliative Chemotherapy with or Without Immunotherapy for Peritoneal Mesothelioma
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|
A092104
|
Alliance
|
A Randomized Phase 2/3 Study of Olaparib plus Temozolomide versus Investigator's Choice for the Treatment of Patients with Advanced Uterine Leiomyosarcoma after Progression on Prior Chemotherapy
|
Adult CIRB - Late Phase Emphasis
|
Available to Open
|
|